DR info

臨床試験数 : 6 / 薬物数 : 11 - (DrugBank : 5) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 2

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

AAV9 BBP-812
   Aspa Therapeutics
      2021   Phase 1/Phase 2   NCT04998396   United States;
GTA (Glyceryl triacetate)
   Shaare Zedek Medical Center
      2008   -   NCT00724802   Israel;
GTA glyceryl triacetate
   Shaare Zedek Medical Center
      2008   -   NCT00724802   Israel;
GTA: Glyceryltriacetate
   Sheba Medical Center
      2006   Phase 1   NCT00278707   Israel;
Levetiracetam
   Myrtelle Inc.
      2021   Phase 1/Phase 2   NCT04833907   United States;
Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)
   Assistance Publique - Hôpitaux de Paris
      2009   Phase 2   NCT00657748   France;
Prednisolone
   Myrtelle Inc.
      2021   Phase 1/Phase 2   NCT04833907   United States;
RAAV-Olig001-ASPA
   Myrtelle Inc.
      2021   Phase 1/Phase 2   NCT04833907   United States;